关键词:
COVID-19
Pulmonary fibrosis
Anti-fibrotic medications
Meta-analysis
COVID-19
PIRFENIDONE
NINTEDANIB
SAFETY
摘要:
Objectives: The impact of anti-fibrotic medications on pulmonary fibrosis caused by COVID-19 remains inconclusive and lacks systematic investigation. This study assessed the efficacy of anti-fibrotic drugs in addressing post-COVID-19 lung fibrosis. Methods: We searched PubMed, Web of Science, Embase, and the Cochrane Library until June 15, 2024. The meta-analysis was performed using Review Manager. Heterogeneity was evaluated utilizing I2 statistic, and publication bias was assessed via funnel plots. Results: The study (CRD42024552847) included 7 trials with 496 participants. No significant differences were observed in chest CT score (SMD =-0.60, 95% CI:-1.33 to 0.12, P = 0.10), length of hospital stay (MD =-1.34, 95% CI:-4.39 to 1.70, P = 0.39), and mortality (OR = 0.91, 95% CI: 0.50 to 1.64, P = 0.75) between anti-fibrosis and standard treatment groups. Notable improvements in pulmonary function were observed with anti-fibrotic drugs, as indicated by FEV1%pred (MD = 23.95, 95% CI: 12.24 to 35.67, P < 0.0 0 01) and FEV1/FVC (MD = 18.17, 95% CI: 11.96 to 24.38, P < 0.0 0 0 01). Conclusions: Anti-fibrotic medications may help reduce fibrotic lesions and improve pulmonary function in post-COVID-19 pulmonary fibrosis, but their practical use is currently based more on theory than on solid medical evidence. Currently, in clinical practice, the use of anti-fibrotic drugs in these patients primarily relies on empirical treatment. Further clinical studies are imperative to bolster its credibility for future applications. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://***/licenses/by-nc-nd/4.0/ )